Published in Biomaterials on February 21, 2013
Materials innovation for co-delivery of diverse therapeutic cargos. RSC Adv (2013) 0.84
Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats. Biomaterials (2013) 0.82
Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates. Pharmaceutics (2016) 0.75
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. J Control Release (2017) 0.75
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol (2008) 7.27
PEGylation, successful approach to drug delivery. Drug Discov Today (2005) 4.56
The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer (2006) 4.55
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res (2003) 3.09
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res (2006) 2.78
Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res (2007) 2.43
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol (2008) 2.10
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol (2011) 2.02
Cell-replacement therapy for diabetes: Generating functional insulin-producing tissue from adult human liver cells. Proc Natl Acad Sci U S A (2005) 1.93
MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol (2008) 1.90
Functional, persistent, and extended liver to pancreas transdifferentiation. J Biol Chem (2003) 1.70
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res (2006) 1.70
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69
Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J (2006) 1.52
Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One (2007) 1.52
Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol Ther (2008) 1.49
Islet-1 gene delivery improves myocardial performance after experimental infarction. Atherosclerosis (2012) 1.43
The angiogenic profile of colorectal cancer patients following open or laparoscopic colectomy. Cancer Biol Ther (2010) 1.41
Dr. Tulp's Anatomy Lesson by Rembrandt: the third day hypothesis. Isr Med Assoc J (2009) 1.40
Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg (2002) 1.30
Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today (2007) 1.29
PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem (2005) 1.27
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res (2004) 1.27
Cytomegalovirus positive ulcerative colitis: A single center experience and literature review. World J Gastrointest Pathophysiol (2013) 1.21
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res (2006) 1.19
Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn (2010) 1.19
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res (2006) 1.18
Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials (2011) 1.17
MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One (2011) 1.15
Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol (2010) 1.15
Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One (2009) 1.15
Tumor-host histopathologic variables, stromal myofibroblasts and risk score, are significantly associated with recurrent disease in tongue cancer. Cancer Sci (2009) 1.14
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A (2008) 1.13
Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res (2011) 1.12
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest (2013) 1.11
A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res (2005) 1.10
Hemangioma of pancreas: a rare tumor of adulthood. Isr Med Assoc J (2011) 1.10
A unique paradigm for a Turn-ON near-infrared cyanine-based probe: noninvasive intravital optical imaging of hydrogen peroxide. J Am Chem Soc (2011) 1.10
Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene (2004) 1.10
A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn (2010) 1.09
Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl (2009) 1.09
Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. Int J Cancer (2010) 1.09
KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res (2011) 1.07
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res (2009) 1.07
Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun (2013) 1.07
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther (2009) 1.07
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther (2008) 1.06
Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug Chem (2011) 1.06
Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res (2011) 1.06
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia (2011) 1.04
A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol (2006) 1.03
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast (2005) 1.02
Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun (2007) 1.02
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res (2006) 1.02
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol (2009) 1.02
Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev (2009) 1.02
Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? J Control Release (2007) 1.01
A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One (2010) 1.00
Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer (2011) 1.00
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther (2007) 0.98
Polymer therapeutics--polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J Drug Target (2006) 0.98
Pancreatic and duodenal homeobox gene 1 induces hepatic dedifferentiation by suppressing the expression of CCAAT/enhancer-binding protein beta. Hepatology (2007) 0.98
A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist (2012) 0.97
Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release (2011) 0.97
Automated cleaning and pre-processing of immunoglobulin gene sequences from high-throughput sequencing. Front Immunol (2012) 0.96
Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. Am J Pathol (2010) 0.96
A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers (2013) 0.96
6''-Thioether tobramycin analogues: towards selective targeting of bacterial membranes. Angew Chem Int Ed Engl (2012) 0.96
Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today (2012) 0.95
Real-time monitoring of drug release. Chem Commun (Camb) (2009) 0.95
A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem (2009) 0.95
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. J Clin Oncol (2006) 0.95
In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J (2010) 0.95
Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem (2007) 0.94
Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. Cancer Lett (2005) 0.94
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J Immunol (2009) 0.94
Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn (2012) 0.94
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood (2011) 0.94
Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest (2004) 0.94
Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm (2011) 0.94
Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells (2008) 0.93
The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg (2005) 0.93
Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Mol Cancer Ther (2005) 0.93
Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res (2008) 0.93
A potential role for islet-1 in post-natal angiogenesis and vasculogenesis. Thromb Haemost (2009) 0.92
Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim Biophys Acta (2010) 0.92
A congenital neutrophil defect syndrome associated with mutations in VPS45. N Engl J Med (2013) 0.92
Endoscopic ultrasound staging of rectal cancer: diagnostic value before and following chemoradiation. J Gastroenterol Hepatol (2006) 0.92
The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochim Biophys Acta (2009) 0.92